These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

505 related articles for article (PubMed ID: 28925400)

  • 1. The HIF and other quandaries in VHL disease.
    Tarade D; Ohh M
    Oncogene; 2018 Jan; 37(2):139-147. PubMed ID: 28925400
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Up-regulation of hypoxia-inducible factors HIF-1alpha and HIF-2alpha under normoxic conditions in renal carcinoma cells by von Hippel-Lindau tumor suppressor gene loss of function.
    Krieg M; Haas R; Brauch H; Acker T; Flamme I; Plate KH
    Oncogene; 2000 Nov; 19(48):5435-43. PubMed ID: 11114720
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Role of VHL gene mutation in human cancer.
    Kim WY; Kaelin WG
    J Clin Oncol; 2004 Dec; 22(24):4991-5004. PubMed ID: 15611513
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Contrasting effects on HIF-1alpha regulation by disease-causing pVHL mutations correlate with patterns of tumourigenesis in von Hippel-Lindau disease.
    Clifford SC; Cockman ME; Smallwood AC; Mole DR; Woodward ER; Maxwell PH; Ratcliffe PJ; Maher ER
    Hum Mol Genet; 2001 May; 10(10):1029-38. PubMed ID: 11331613
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The VHL tumor suppressor and HIF: insights from genetic studies in mice.
    Kapitsinou PP; Haase VH
    Cell Death Differ; 2008 Apr; 15(4):650-9. PubMed ID: 18219317
    [TBL] [Abstract][Full Text] [Related]  

  • 6. VHL disease.
    Barontini M; Dahia PL
    Best Pract Res Clin Endocrinol Metab; 2010 Jun; 24(3):401-13. PubMed ID: 20833332
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The von Hippel-Lindau tumor suppressor protein: roles in cancer and oxygen sensing.
    Kaelin WG
    Cold Spring Harb Symp Quant Biol; 2005; 70():159-66. PubMed ID: 16869749
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hypoxia, Hypoxia-inducible Transcription Factors, and Renal Cancer.
    Schödel J; Grampp S; Maher ER; Moch H; Ratcliffe PJ; Russo P; Mole DR
    Eur Urol; 2016 Apr; 69(4):646-657. PubMed ID: 26298207
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Renal cell carcinoma- and pheochromocytoma-specific altered gene expression profiles in VHL mutant clones.
    Tsuchiya MI; Okuda H; Takaki Y; Baba M; Hirai S; Ohno S; Shuin T
    Oncol Rep; 2005 Jun; 13(6):1033-41. PubMed ID: 15870918
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Identification of cyclin D1 and other novel targets for the von Hippel-Lindau tumor suppressor gene by expression array analysis and investigation of cyclin D1 genotype as a modifier in von Hippel-Lindau disease.
    Zatyka M; da Silva NF; Clifford SC; Morris MR; Wiesener MS; Eckardt KU; Houlston RS; Richards FM; Latif F; Maher ER
    Cancer Res; 2002 Jul; 62(13):3803-11. PubMed ID: 12097293
    [TBL] [Abstract][Full Text] [Related]  

  • 11. von Hippel-Lindau protein mutants linked to type 2C VHL disease preserve the ability to downregulate HIF.
    Hoffman MA; Ohh M; Yang H; Klco JM; Ivan M; Kaelin WG
    Hum Mol Genet; 2001 May; 10(10):1019-27. PubMed ID: 11331612
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Genotype-phenotype analysis of von Hippel-Lindau syndrome in Korean families: HIF-α binding site missense mutations elevate age-specific risk for CNS hemangioblastoma.
    Lee JS; Lee JH; Lee KE; Kim JH; Hong JM; Ra EK; Seo SH; Lee SJ; Kim MJ; Park SS; Seong MW
    BMC Med Genet; 2016 Jul; 17(1):48. PubMed ID: 27439424
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Algorithmic assessment of missense mutation severity in the Von-Hippel Lindau protein.
    Fields FR; Suresh N; Hiller M; Freed SD; Haldar K; Lee SW
    PLoS One; 2020; 15(11):e0234100. PubMed ID: 33151962
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Coalescing lessons from oxygen sensing, tumor metabolism, and epigenetics to target VHL loss in kidney cancer.
    Chakraborty AA
    Semin Cancer Biol; 2020 Dec; 67(Pt 2):34-42. PubMed ID: 32209418
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Identification of membrane type-1 matrix metalloproteinase as a target of hypoxia-inducible factor-2 alpha in von Hippel-Lindau renal cell carcinoma.
    Petrella BL; Lohi J; Brinckerhoff CE
    Oncogene; 2005 Feb; 24(6):1043-52. PubMed ID: 15592504
    [TBL] [Abstract][Full Text] [Related]  

  • 16. VHL mutations linked to type 2C von Hippel-Lindau disease cause extensive structural perturbations in pVHL.
    Knauth K; Cartwright E; Freund S; Bycroft M; Buchberger A
    J Biol Chem; 2009 Apr; 284(16):10514-22. PubMed ID: 19228690
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Molecular targets from VHL studies into the oxygen-sensing pathway.
    Maynard MA; Ohh M
    Curr Cancer Drug Targets; 2005 Aug; 5(5):345-56. PubMed ID: 16101382
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The protein tyrosine phosphatase receptor type J is regulated by the pVHL-HIF axis in clear cell renal cell carcinoma.
    Casagrande S; Ruf M; Rechsteiner M; Morra L; Brun-Schmid S; von Teichman A; Krek W; Schraml P; Moch H
    J Pathol; 2013 Mar; 229(4):525-34. PubMed ID: 23007793
    [TBL] [Abstract][Full Text] [Related]  

  • 19. von Hippel-Lindau disease: a clinical and scientific review.
    Maher ER; Neumann HP; Richard S
    Eur J Hum Genet; 2011 Jun; 19(6):617-23. PubMed ID: 21386872
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Nervous system involvement in von Hippel-Lindau disease: pathology and mechanisms.
    Vortmeyer AO; Falke EA; Gläsker S; Li J; Oldfield EH
    Acta Neuropathol; 2013 Mar; 125(3):333-50. PubMed ID: 23400300
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.